HER-2 Protein Overexpression clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

    open to eligible people ages 18 years and up

    This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.

    Los Angeles, California and other locations

Our lead scientists for HER-2 Protein Overexpression research studies include .

Last updated: